- Home
- GYRE vs KIND Comparison
GYRE vs KIND Comparison
Compare GYRE & KIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- KIND
- Stock Information
- Founded
- GYRE 2002
- KIND 2011
- Country
- GYRE United States
- KIND United States
- Employees
- GYRE N/A
- KIND N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- KIND Computer Software: Programming Data Processing
- Sector
- GYRE Health Care
- KIND Technology
- Exchange
- GYRE Nasdaq
- KIND Nasdaq
- Market Cap
- GYRE 997.3M
- KIND 1.0B
- IPO Year
- GYRE N/A
- KIND N/A
- Fundamental
- Price
- GYRE $11.54
- KIND $2.58
- Analyst Decision
- GYRE
- KIND Buy
- Analyst Count
- GYRE 0
- KIND 3
- Target Price
- GYRE N/A
- KIND $3.17
- AVG Volume (30 Days)
- GYRE 53.5K
- KIND 1.4M
- Earning Date
- GYRE 03-25-2025
- KIND 02-27-2025
- Dividend Yield
- GYRE N/A
- KIND N/A
- EPS Growth
- GYRE N/A
- KIND N/A
- EPS
- GYRE N/A
- KIND N/A
- Revenue
- GYRE $105,033,000.00
- KIND $237,605,000.00
- Revenue This Year
- GYRE $25.32
- KIND $14.90
- Revenue Next Year
- GYRE $12.95
- KIND $14.38
- P/E Ratio
- GYRE N/A
- KIND N/A
- Revenue Growth
- GYRE N/A
- KIND 9.99
- 52 Week Low
- GYRE $8.26
- KIND $1.91
- 52 Week High
- GYRE $26.37
- KIND $3.00
- Technical
- Relative Strength Index (RSI)
- GYRE 47.99
- KIND 46.73
- Support Level
- GYRE $12.09
- KIND $2.64
- Resistance Level
- GYRE $12.80
- KIND $2.76
- Average True Range (ATR)
- GYRE 0.56
- KIND 0.10
- MACD
- GYRE -0.00
- KIND -0.01
- Stochastic Oscillator
- GYRE 16.39
- KIND 33.33
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.